Research

Research

Home
Research

Acute Promyelocytic Leukaemia (APL)

P493: ORAL-ATO/ATRA/ASCORBIC ACID (AAA)-BASED INDUCTION OR MAINTENANCE OF FIRST COMPLETE REMISSION IMPROVED OUTCOMES IN NEWLY DIAGNOSED APL: A MULTICENTRE ANALYSIS OF THE APL ASIAN CONSORTIUM (APLAC)

S133: AN ENTIRELY ORAL REGIMEN OF ORAL-ATO, ATRA AND ASCORBIC ACID IN RISK-ADAPTED TREATMENT OF NEWLY-DIAGNOSED APL RESULTED IN EXCELLENT CLINICAL/MOLECULAR RESPONSES WITH DURABLE REMISSION

Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021

Editorial: Acute Promyelocytic Leukemia — Towards A Chemotherapy-Free Approach to Cure in All Patients

Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond

The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases

Epidemiology and outcomes of acute promyelocytic leukaemia in the era of all-trans retinoic acid (ATRA) chemotherapy and arsenic trioxide plus ATRA: a retrospective analysis

Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study

Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside

Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators

Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study

Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study

Myelodysplastic Syndrome (MDS)

Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents

Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing Platform

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome

Acute Myeloid Leukaemia (AML)

Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation

Myeloproliferative Neoplasm (MPN)

Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group

S211: EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B FOR PRE-FIBROTIC PRIMARY MYELOFIBROSIS AND DIPSS LOW/INTERMEDIATE-1 RISK MYELOFIBROSIS: UPDATED RESULTS AND GENOMIC CHARACTERISTICS

Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting

Key Opinions in Medicine: Management Strategies in Early Myelofibrosis

2022 Asian Myeloid Malignancies Exchange Forum

Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)

Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis

SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia

P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms

Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis

Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment

Predictors of Vascular Events and Disease Transformation in Chinese Patients with Myeloproliferative Neoplasms during Long-Term Follow-up

Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis

Copyright © 2023 AMWG. All rights reserved.

Oncology Academy

分享到微信朋友圈

打開微信，點擊底部的「發現」，使用「掃一掃」即可將網頁分享到我的朋友圈。

分享到微信朋友圈

請複製以下連結，然後分享到微信